Xencor (XNCR) Stock Rating Upgraded by BidaskClub

Xencor (NASDAQ:XNCR) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday.

A number of other research firms have also recently weighed in on XNCR. Cantor Fitzgerald initiated coverage on Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price target on the stock. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Zacks Investment Research reaffirmed a “sell” rating on shares of Xencor in a report on Saturday, January 13th. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.80.

Xencor (NASDAQ:XNCR) traded down $0.61 on Wednesday, hitting $23.36. The stock had a trading volume of 74,533 shares, compared to its average volume of 135,111. The company has a market capitalization of $1,125.65, a PE ratio of -23.36 and a beta of 2.09. Xencor has a 52 week low of $18.55 and a 52 week high of $28.64.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. analysts forecast that Xencor will post -1.1 earnings per share for the current year.

In other news, major shareholder John S. Stafford III bought 13,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were purchased at an average price of $19.81 per share, with a total value of $271,397.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were purchased at an average cost of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 103,882 shares of company stock worth $2,062,130. 4.03% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in XNCR. Great West Life Assurance Co. Can grew its position in Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares during the last quarter. Legal & General Group Plc grew its position in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Xencor in the third quarter worth approximately $201,000. Citadel Advisors LLC acquired a new position in Xencor in the second quarter worth approximately $224,000. Finally, Voya Investment Management LLC grew its position in Xencor by 25.4% in the second quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 3,405 shares during the last quarter. 77.50% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Xencor (XNCR) Stock Rating Upgraded by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/28/xencor-xncr-stock-rating-upgraded-by-bidaskclub.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply